GlaxoSmithKline Arranon
Executive Summary
GSK arabinoside prodrug Arranon (nelarabine) will be reviewed on Sept. 14 by the Oncologic Drugs Advisory Committee for treatment of patients with T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma whose disease has not responded to, or has relapsed with, at least two chemotherapy regimens. GSK completed a rolling NDA submission (21-877) for Arranon on April 29 based on Phase II data...